Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2006

View Archived Issues

IND filing for XL-281

R-1626 begins phase II trials in chronic hepatitis C

Agreement for humanization of BioArctic's antibody for Alzheimer's disease

Phoqus to advance Chronocort into phase II trials for adrenal insufficiency

Delay to gaboxadol NDA filing

G-4460 studied in phase I trial in advanced cancer

End-of-phase II meeting for NRP-290

Taiho follows committee's advice on gastric cancer study of TS-1

Improved outcomes with Surfaxin in bronchopulmonary dysplasia

Polidocasklerol for varicose veins set for December launch in Japan

Novo Nordisk withdraws E.U. application to expand repaglinide product labels

Neurochem submits complete response to Kiacta approvable letter

BVT-28949 begins phase II study for glaucoma

Tezampanel begins phase IIb for treatment of acute migraine

AD-337 studied in fibromyalgia syndrome proof-of-principle study

Ad5-TRAIL gene therapy studied in phase I for prostate cancer

XEN-D0101 begins phase I development for atrial fibrillation

New data presented at EADV on agents under development at Barrier Therapeutics

Retapamulin effective in treating impetigo

Preclinical studies detail CNS-7056X characteristics

New therapeutics for cancer covered in recent patent literature

Novel agents for thrombotic disorders reported in recent Pfizer and Fournier patents

New peptides for treating wrinkles reported by Rohto

Novel choline analogue enhances cognition in monkeys

Targeting sEH as a novel strategy for inflammatory pain relief

SP-04 and its metabolite: a novel therapeutic approach for Alzheimer's disease

Spotlight on novel macrolide derivatives developed at Enanta

FDA accepts NDA for zileuton CR

Januvia approved for type 2 diabetes

NovoSeven approved for acquired hemophilia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...